Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.59 |
| ▸ | CDK4 | P11802 | 5/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.44 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6598183 | 0.90 | CDK2 (0.64) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL5102624 | 0.88 | CDK2 (0.56) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL5108295 | 0.88 | CDK2 (0.56) | CDK2CDK4CCNA2CCNA1 | |
| SCHEMBL5095601 | 0.87 | CDK2 (0.54) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL5098992 | 0.85 | CDK2 (0.60) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL6594422 | 0.84 | CDK2 (0.66) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL6387030 | 0.83 | CDK2 (0.60) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL4021384 | 0.82 | CDK2 (0.68) | CDK2CDK4CCNA2CCNA1 | |
| SCHEMBL6106036 | 0.82 | CDK2 (0.64) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL5108359 | 0.81 | CDK2 (0.52) | CDK2CDK4CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442697-B2 | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | claimed |
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | MOTOROLA MOBILITY LLC | 2006-04-06 | — | — | US | claimed |
| EP-1490354-A1 | 4-IMIDAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES WITH CDK INHIBITORY ACTIVITY | Astrazeneca AB (SE) | 2004-12-29 | — | — | EP | claimed |
| WO-2003076434-A1 | 4- IMIDAZOLYL SUBSTUITED PYRIMIDINE DERIVATIVES WITH CDK INHIBITIORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | WO | claimed |
| US-7442697-B2 | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | MOTOROLA MOBILITY LLC | 2006-04-06 | — | — | US | disclosed |
| EP-1490354-A1 | 4-IMIDAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES WITH CDK INHIBITORY ACTIVITY | Astrazeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003076434-A1 | 4- IMIDAZOLYL SUBSTUITED PYRIMIDINE DERIVATIVES WITH CDK INHIBITIORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | CCNI, CDK3, CDK4 | CDK2 6/4885CDK4 3/4885CCNA2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.